Skip to main content
. 2020 Aug 24;38(30):3494–3505. doi: 10.1200/JCO.19.03107

FIG 2.

FIG 2.

Quality-adjusted progression-free survival (QA-PFS) in the intent-to-treat population (A), BRCA-mutant cohort (B), homologous recombination deficient cohort (C), BRCA wild-type/loss of heterozygosity (LOH) high (D), BRCA wild-type/LOH low (E), and BRCA wild-type/LOH indeterminate (F) patient subgroups. Patients at-risk data are shown for the progression-free survival (PFS) analysis.